Literature DB >> 22326260

Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection.

Larisa Dubrovsky1, Rachel Van Duyne, Svetlana Senina, Irene Guendel, Tatiana Pushkarsky, Dmitri Sviridov, Fatah Kashanchi, Michael Bukrinsky.   

Abstract

HIV-infected subjects are at high risk of developing atherosclerosis, in part due to virus-induced impairment of HDL metabolism. Here, using as a model of HIV infection the NOD.Cg-Prkdc(scid)IL2rg(tm1Wjl)/SzJ (NSG) mice humanized by human stem cell transplantation, we demonstrate that LXR agonist TO901317 potently reduces viral replication and prevents HIV-induced reduction of plasma HDL. These results establish that humanized mice can be used to investigate the mechanisms of HIV-induced impairment of HDL formation, a major feature of dyslipidemia associated with HIV-1 infection, and show potential benefits of developing LXR agonists for treatment of HIV-associated cardio-vascular disease.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326260      PMCID: PMC3294093          DOI: 10.1016/j.bbrc.2012.01.137

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

1.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

2.  Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages.

Authors:  E Rigamonti; L Helin; S Lestavel; A L Mutka; M Lepore; C Fontaine; M A Bouhlel; S Bultel; J C Fruchart; E Ikonen; V Clavey; B Staels; G Chinetti-Gbaguidi
Journal:  Circ Res       Date:  2005-09-01       Impact factor: 17.367

3.  Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy.

Authors:  Steen B Haugaard; Ove Andersen; Steen B Pedersen; Flemming Dela; Mogens Fenger; Bjørn Richelsen; Sten Madsbad; Johan Iversen
Journal:  Metabolism       Date:  2006-02       Impact factor: 8.694

4.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

5.  Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Authors:  Leonard D Shultz; Bonnie L Lyons; Lisa M Burzenski; Bruce Gott; Xiaohua Chen; Stanley Chaleff; Malak Kotb; Stephen D Gillies; Marie King; Julie Mangada; Dale L Greiner; Rupert Handgretinger
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

6.  Effect of transcription peptide inhibitors on HIV-1 replication.

Authors:  Rachel Van Duyne; Jessica Cardenas; Rebecca Easley; Weilin Wu; Kylene Kehn-Hall; Zak Klase; Susana Mendez; Chen Zeng; Hao Chen; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Virology       Date:  2008-05-02       Impact factor: 3.616

7.  HIV infection and high density lipoprotein metabolism.

Authors:  Honor Rose; Jennifer Hoy; Ian Woolley; Urbain Tchoua; Michael Bukrinsky; Anthony Dart; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2007-12-04       Impact factor: 5.162

Review 8.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

9.  Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles.

Authors:  Aldo Grefhorst; Baukje M Elzinga; Peter J Voshol; Torsten Plösch; Tineke Kok; Vincent W Bloks; Fjodor H van der Sluijs; Louis M Havekes; Johannes A Romijn; Henkjan J Verkade; Folkert Kuipers
Journal:  J Biol Chem       Date:  2002-07-03       Impact factor: 5.157

10.  HIV and cardiovascular disease: contribution of HIV-infected macrophages to development of atherosclerosis.

Authors:  Michael Bukrinsky; Dmitri Sviridov
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

View more
  13 in total

Review 1.  New generation humanized mice for virus research: comparative aspects and future prospects.

Authors:  Ramesh Akkina
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

2.  Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation.

Authors:  Ruth Hunegnaw; Marina Vassylyeva; Larisa Dubrovsky; Tatiana Pushkarsky; Dmitri Sviridov; Anastasia A Anashkina; Aykut Üren; Beda Brichacek; Dmitry G Vassylyev; Alexei A Adzhubei; Michael Bukrinsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-28       Impact factor: 8.311

Review 3.  Sterols and oxysterols in immune cell function.

Authors:  Nathanael J Spann; Christopher K Glass
Journal:  Nat Immunol       Date:  2013-09       Impact factor: 25.606

Review 4.  Liver X receptors link lipid metabolism and inflammation.

Authors:  Ira G Schulman
Journal:  FEBS Lett       Date:  2017-06-13       Impact factor: 4.124

5.  LXR Alpha Restricts Gammaherpesvirus Reactivation from Latently Infected Peritoneal Cells.

Authors:  P T Lange; C N Jondle; E J Darrah; K E Johnson; V L Tarakanova
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

6.  Modelling interaction between HIV-1 Nef and calnexin.

Authors:  Alexei A Adzhubei; Anastasia A Anashkina; Yaroslav V Tkachev; Yury V Kravatsky; Tatiana Pushkarsky; Amol Kulkarni; Alexander A Makarov; Michael I Bukrinsky
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

7.  Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.

Authors:  Ramesh Akkina; Atef Allam; Alejandro B Balazs; Joel N Blankson; John C Burnett; Sofia Casares; J Victor Garcia; Kim J Hasenkrug; Fatah Kashanchi; Scott G Kitchen; Florian Klein; Priti Kumar; Andrew D Luster; Larisa Y Poluektova; Mangala Rao; Brigitte E Sanders-Beer; Leonard D Shultz; Jerome A Zack
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

8.  HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis.

Authors:  Huanhuan L Cui; Michael Ditiatkovski; Rajitha Kesani; Yuri V Bobryshev; Yingying Liu; Matthias Geyer; Nigora Mukhamedova; Michael Bukrinsky; Dmitri Sviridov
Journal:  FASEB J       Date:  2014-03-18       Impact factor: 5.191

9.  Stimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection.

Authors:  Ali Ramezani; Larisa Dubrovsky; Tatiana Pushkarsky; Dmitri Sviridov; Sara Karandish; Dominic S Raj; Michael L Fitzgerald; Michael Bukrinsky
Journal:  J Pharmacol Exp Ther       Date:  2015-06-30       Impact factor: 4.030

10.  HIV-1 protein Nef inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexin.

Authors:  Lucas Jennelle; Ruth Hunegnaw; Larisa Dubrovsky; Tatiana Pushkarsky; Michael L Fitzgerald; Dmitri Sviridov; Anastas Popratiloff; Beda Brichacek; Michael Bukrinsky
Journal:  J Biol Chem       Date:  2014-08-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.